Stock Updates

Is this Large Market Cap Stock target price reasonable for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)?

The company in question is, Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) currently with a stock price of 127.21 (-1.61% today). The market cap for Alexion Pharmaceuticals, Inc. is 30186.63, and is in the sector Healthcare, and Biotechnology industry. The target price for Alexion Pharmaceuticals, Inc. is 171.75. Currently Alexion Pharmaceuticals, Inc. is trading with a P/E of 327.32, and a forward P/E of 21.62. Average volume for Alexion Pharmaceuticals, Inc. is 1864.18 and so far today it is 152371.

Performance in the last year for Alexion Pharmaceuticals, Inc. has been -24.80%. For EPS growth, Alexion Pharmaceuticals, Inc. has seen a growth of -79.50%, and is looking to grow in the next year to 28.64%. More long term stats show that EPS growth has been 5.10% over the last five years and could be 18.28% for the next five years. Alexion Pharmaceuticals, Inc. has seen sales growth quarter over quarter at 18.40%, with EPS growth quarter over quarter at -38.80%. The 20-day simple moving average is -1.39%, with the 200-day simple moving average coming to -12.58%.

Since the IPO date for Alexion Pharmaceuticals, Inc. on the 2/28/1996, Alexion Pharmaceuticals, Inc. has seen performance year to date to be -32.22%. With Alexion Pharmaceuticals, Inc. trading at 127.21, the dividend yield is *TBA, and the EPS is 0.4.

So could Alexion Pharmaceuticals, Inc., be undervalued? Well as said before P/E is 327.32. The PEG is 17.9, P/S is 10.7 and the P/B is at 3.53. The P/cash is 25.58, with P/free cash flow at 56.04.

Alexion Pharmaceuticals, Inc. ability to deal with debt shows that the current ratio is 3.6, and the quick ratio is 3.1. This is with long term debt/equity at 0.39, and total debt/equity at 0.4.

In terms of margins, Alexion Pharmaceuticals, Inc. has a gross margin of 91.80%, an operating margin of 21.70% and a profit margin of 3.20%.Payout ratio for Alexion Pharmaceuticals, Inc. is 0.00%. Return on assets come to 0.70% with return on investment coming to 1.60%.

Insider ownership for Alexion Pharmaceuticals, Inc., is at 0.50% and institutional ownership comes to 98.30%. Outstanding shares are at 233.48. While shares float is 223.42. The float short is currently 2.70%, and short ratio is 3.23.

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.

About the author

Mark Hines

Leave a Comment